使用帕唑帕尼联合 PD-1 抑制剂和 RAK 细胞治疗晚期原发性肝血管肉瘤：一例报告。
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report.
机构信息
Department of Geriatric, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
Department of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
出版信息
BMC Cancer. 2018 Feb 21;18(1):212. doi: 10.1186/s12885-018-3996-3.
BACKGROUND
Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA.
CASE PRESENTATION
A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor.
CONCLUSION
Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
背景
原发性肝血管肉瘤（PHA）是一种罕见且侵袭性的实体肿瘤，局部复发和远处转移率高，预后差。目前尚无针对 PHA 的既定治疗指南。
病例介绍
一名 78 岁无症状男性，患有 PHA，经 pazopanib 联合 PD-1 抑制剂和 RetroNectin 激活杀伤细胞（RAK 细胞）治疗后成功。治疗一个月后，肝转移瘤的大小和数量明显减少；近 15 个月后，大部分病灶稳定，无新病灶出现，治疗副作用较小。
结论
pazopanib、PD-1 抑制剂和 RAK 细胞可能是治疗晚期 PHA 的一种潜在选择。
Zotero 插件